患者组织在药物警戒中的障碍及促进其参与的策略
本研究采用序贯定性方法并与Matos、Weits和van Hunsel的定量研究整合为混合方法研究,旨在了解患者组织对药物警戒的认知、实施药物警戒活动时面临的障碍、与其他利益相关方的互动,并提出促进患者组织作为药物警戒推动者的方法。定性阶段拓展了定量结果,揭示患者组织面临内部与外部障碍,并提出多种促进策略。两阶段结果一致:患者组织正逐步成为药物警戒利益相关方,但内部和外部障碍仍可能妨碍其参与。
要点
- 患者组织对药物警戒认知不足且缺乏参与经验。
- 患者组织面临内部与外部障碍,妨碍其参与药物警戒活动。
- 促进策略包括宣传、教育、针对性系统和主动监管 approach。
核心结论
- 两阶段研究结果一致:患者组织正逐步成为药物警戒利益相关方,开展多种活动促进成员对药物安全的认知和参与,但仍面临内部和外部障碍妨碍其参与。
研究设计与样本
- 序贯定性方法研究,并与Matos、Weits和van Hunsel的定量研究整合为混合方法研究。
主要发现
- 定性阶段拓展了对定量结果的理解,加深了患者组织在实施药物警戒活动时面临的外部障碍和内部障碍的认识。
- 促进患者组织参与的策略包括:开展更多宣传运动、开展更多能提高认知的研究、对患者组织进行教育、传播真实的药物警戒案例、建立针对性药物警戒系统、建立向患者提供反馈的药物警戒沟通网络、增进所有利益相关方的理解、国家主管当局采取更主动的方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: European drug regulations aim for a patient-centered approach, including involving patients in the pharmacovigilance (PV) systems. However many patient organizations have little experience on how they can participate in PV activities. AIM: The aim of this study was to understand patient organizations' perceptions of PV, the barriers they face when implementing PV activities, and their interaction with other stakeholders and suggest methods for the stimulation of patient organizations as promoters of PV. METHODS: A sequential qualitative method study was conducted and integrated with the quantitative study performed by Matos, Weits, and van Hunsel to complete a mixed method study. RESULTS: The qualitative phase expands the understanding of the quantitative results from a previous study by broadening the knowledge on external barriers and internal barriers that patient organizations face when implementing PV activities. The strategies to stimulate patient-organization participation are the creation of more awareness campaigns, more research that creates awareness, education for patient organizations, communication of real PV examples, creation of a targeted PV system, creation of a PV communication network that provides feedback to patients, improvement of understanding of all stakeholders, and a more proactive approach from national competent authorities. CONCLUSION: Both study phases show congruent results regarding patients' involvement and the activities patient organizations perform to promote drug safety. Patient organizations progressively position themselves as stakeholders in PV, carrying out many activities that stimulate awareness and participation of their members in drug safety, but still face internal and external barriers that can hamper their involvement.
引用
- Chinchilla K, Matos C, Hall V, et al. Patient Organizations' Barriers in Pharmacovigilance and Strategies to Stimulate Their Participation. Drug Saf. 2020. PMID: 32989664. doi:10.1007/s40264-020-00999-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。